Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002882 · ClinicalTrials.gov registry record · Phase 3
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00002882: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00002882 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002882, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treating patients with melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy plus interleukin-2 in treating patients with melanoma.
Interventions
- DRUG Cisplatin
- DRUG Dacarbazine
- DRUG Vinblastine
- BIOLOGICAL Aldesleukin (IL-2)
- BIOLOGICAL Recombinant Interferon Alfa (IFN-A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 1995-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002882
The ClinicalTrials.gov registry entry for NCT00002882 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00002882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002882 about?
NCT00002882 is a clinical study titled "Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treat...
What is the current status of trial NCT00002882?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 1995-11. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00002882?
The interventions under investigation include: Cisplatin (DRUG), Dacarbazine (DRUG), Vinblastine (DRUG), Aldesleukin (IL-2) (BIOLOGICAL), Recombinant Interferon Alfa (IFN-A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002882?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.